Articles related to CLONAL HEMATOPOIESIS (CHIP)

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

“CHIP, especially non-DNMT3A CHIP, was independently associated with incident HF. Future research should explore the gene-specific mechanisms by which CHIP variants promote HF in humans.” — Study Authors, JAMA Cardiology

The surprising association between CHIP and a lowered risk of Alzheimer’s disease offers a novel perspective in our understanding of neurodegenerative disorders and paves the way for potential future therapeutics.

Responses to conventional donor lymphocyte infusion for post-allogeneic hematopoietic cell transplantation relapse are typically poor. Natural killer cell-based therapy is a promising modality to treat post-HCT relapse. This ongoing phase I trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT saw a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires.

The authors analyzed the outcome of 349 patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. After a median follow-up of 5.9 years, estimated 5-year overall survival was between the two groups, and median overall survival was not reached. In terms of relapse, five-year incidence was 30% for the accelerated-phase group versus 15% for the chronic-phase group. Reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.

In this late-breaking abstract from the ASH Annual Meeting & Exhibition, the researches wanted to address the limited understanding of how and when CH develops, what factors govern its behavior, how it interacts with aging, and how these variables relate to malignant progression. Here are the results from analyzing 1,593 blood DNA samples from 385 elderly individuals, each sampled up to 5 times over approximately 13 years.